Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Core Viewpoint - Aprea Therapeutics, Inc. is actively participating in the Maxim Healthcare Virtual Summit, showcasing its focus on precision oncology through synthetic lethality [1][4]. Group 1: Company Overview - Aprea Therapeutics is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, specializing in precision oncology [4]. - The company's lead program is ATRN-119, a small molecule ATR inhibitor aimed at treating solid tumors [4]. - Aprea has recently initiated clinical development for APR1051, an oral small-molecule WEE1 inhibitor [4]. Group 2: Event Participation - Dr. Oren Gilad, President and CEO of Aprea, will present at two sessions during the Maxim Healthcare Virtual Summit [1]. - The first session is a Precision and Immune Oncology Panel scheduled for October 16, 2024, from 2:00 to 3:00 PM ET [2]. - The second session is a Fireside Chat on October 17, 2024, from 3:30 to 4:00 PM ET [2].